Lexaria Bioscience Corp Warrant 2020-12.01.26 on Lexaria Bioscience LEXXW 深 滬
已收盤 09-19 16:00:00 美东时间
0.0748
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 4股
- 最 低 --
- 昨 收 0.0748
- 總市值 38.18万
- 52周最高 1.31
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0507
- 委 比 -7.48%
- 總股本 510.43万
- 歷史最高 5.19
- 量 比 0.00
- 振 幅 0.00%
- 歷史最低 0.05
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexaria Bioscience Announces Results From Fluorescently Tagged Semaglutide Rodent Biodistribution Study
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery
09-19 23:22
Lexaria Bioscience’s DehydraTECH Boosts Semaglutide Brain Delivery
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience has ann...
09-19 23:07
Lexaria Bioscience's Contract Research Organization Completes Last Patent Last Visit Study Milestone In Lexaria's Phase 1b Glucagon-Like Peptide-1 Study In Australia, GLP-1-H24-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the
08-14 21:23
Lexaria Bioscience Targets GLP-1 Market with DehydraTECH Innovation
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience is posi...
08-06 22:42
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf
07-31 22:58
Lexaria’s DehydraTECH Technology Poised to Transform GLP-1 Industry
Lexaria Bioscience ( ($LEXX) ) just unveiled an announcement. Lexaria Bioscienc...
07-23 23:09
Lexaria's DehydraTECH Targets Side Effects In GLP-1 Market, Offers Relief For Semaglutide, Tirzepatide, And Liraglutide Users
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:29
Lexaria Bioscience Prpvides Strategic Update Of Glucagon-Like Peptide-1
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:28
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
Lexaria Bioscience Q3 EPS $(0.21) Misses $(0.16) Estimate, Sales $174.000K Beat $91.333K Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 33.76 percent. This is a 61.54 percent decrease over losses of $(0.13) per share
07-15 06:32
